farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909.2019.12.2.146-154farmaec-294Research ArticleINTERNATIONAL PRACTICESЗАРУБЕЖНЫЙ ОПЫТOrganizational structure and funding of health technology assessment agencies around the worldМеждународный опыт организации и финансового обеспечения агентств по оценке технологий здравоохраненияhttps://orcid.org/0000-0002-7340-2698ХачатрянГ. Р.KhachatryanG. R.

Хачатрян Георгий Рубенович - начальник отдела методологического обеспечения проведения комплексной оценки технологий в здравоохранении ФГБУ «ЦЭККМП» МР, младший научный сотрудник ЦФЗ НИФИ МР.

Настасьинский пер., д. 3, стр. 2, Москва 127006; Хохловский пер., вл. 10, стр. 5, Москва 109028

Georgii R. Khachatryan - Head of the Department of Methodological Support of Comprehensive Health Technology Assessment CHQAC; Junior Researcher at the Center for Healthcare Funding, FRI.

3-2 Nastasyinsky pereulok, Moscow 127006; 10-5 Khokhlovskii pereulok, Moscow 109028

khachatryan-george@ya.ruhttps://orcid.org/0000-0003-1581-0703ОмельяновскийВ. В.OmelyanovskiyV. V.

Омельяновский Виталий Владимирович - доктор медицинских наук, профессор, генеральный директор ЦЭиКМП; руководитель Центра финансов здравоохранения Научно-исследовательского финансового института Министерства финансов РФ.; ResearcherID: P-6911-2018; ScopusAuthorID: 6507287753.

Настасьинский пер., д. 3, стр. 2, Москва 127006; просп. Вернадского, д. 82, Москва 119571

Vitaly V. Omelyanovskiy - MD, PhD, Professor, Head of the Healthcare Finance Center FRI, Researcher ID: P-6911-2018; Scopus Author ID: 6507287753.

3-2 Nastasyinsky pereulok, Moscow 127006; 82 Vernadskogo prospect, Moscow 119571

МельниковаЛ. С.MelnikovaL. S.

Мельникова Любовь Сергеевна - доктор медицинских наук, ведущий научный сотрудник ЦЭиКМП.

Настасьинский пер., д. 3, стр. 2, Москва 127006; Хохловский пер., вл. 10, стр. 5, Москва 109028

Lyubov S. Melnikova - MD, PhD, Leading Researcher FRI.

3-2 Nastasyinsky pereulok, Moscow 127006; 10-5 Khokhlovskii pereulok, Moscow 109028

РатушнякС. С.RatushnyakS. S.

Ратушняк Светлана Сергеевна - ведущий специалист отдела методологического обеспечения проведения комплексной оценки технологий в здравоохранении.

Хохловский пер., вл. 10, стр. 5, Москва 109028

Svetlana S. Ratushnyak- Leading Specialist at the Department of Methodological Support of Comprehensive HTA, CHQAC.

3-2 Nastasyinsky pereulok, Moscow 127006

Федеральное государственное бюджетное учреждение Научно-исследовательский финансовый институт Министерства финансов Российской Федерации; Федеральное государственное бюджетное учреждение «Центр экспертизы и контроля качества медицинской помощи» Министерства здравоохранения Российской ФедерацииРоссияResearch Institute of Finance, Ministry of Finance of the Russian Federation; Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian FederationRussian FederationФедеральное государственное бюджетное учреждение Научно-исследовательский финансовый институт Министерства финансов Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Российская академия народного хозяйства и государственной службы при Президенте Российской ФедерацииРоссияResearch Institute of Finance, Ministry of Finance of the Russian Federation; Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional EducationRussian FederationФедеральное государственное бюджетное учреждение «Центр экспертизы и контроля качества медицинской помощи» Министерства здравоохранения Российской ФедерацииРоссияResearch Institute of Finance, Ministry of Finance of the Russian FederationRussian Federation201918072019122146154Copyright © Khachatryan G.R., Omelyanovskiy V.V., Melnikova L.S., Ratushnyak S.S., 20192019Хачатрян Г.Р., Омельяновский В.В., Мельникова Л.С., Ратушняк С.С.Khachatryan G.R., Omelyanovskiy V.V., Melnikova L.S., Ratushnyak S.S.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/294Aim

Aim: analyze the structure and funding of health technology assessment (HTA) agencies abroad.

Materials and methods

Materials and methods. Here, we review the organizational structure and funding of HTA agencies in Europe (Austria, Belgium, Germany, Ireland, the Netherlands, the United Kingdom, France, and Sweden), Canada and Australia. The relevant information was found on web-sites of HTA agencies, in the Medline database, and via the searching engines Yandex and Google; the search was conducted using the specific descriptors: «organizational structure of HTA agency», «funding of HTA agency», «pharmaceutical», «reimbursement», «healthcare decision-making», and «funding».

Results

Results. The identified HTA-agencies may have a status of either government-funded or nonprofit organization or a structural element of a governmental body. These hTa agencies are funded mainly from the national budget. The funding varies from €550 000 for Ireland to £63.1 mln (€70 million) for the National Institute for Clinical Excellence (NICE) in the UK. The number of employees in the reviewed HTA agencies varies from 6.8 full time employees (FTE) in the Health Information and Quality Authority (HIQA) in Ireland to 604 FTEs in the NICE.

Цель - представляется актуальным изучение зарубежного опыта организации работы и финансирования организаций, ответственных за проведение оценки технологий здравоохранения (ОТЗ).

Материалы и методы

Материалы и методы. Проведен анализ международного опыта организации работы и финансового обеспечения агентств по ОТЗ в странах Европы (Австрия, Бельгия, Германия, Ирландия, Нидерланды, Соединенной Королевство Великобритании и Северной Ирландии, Франция, Швеция), а также в Канаде и в Австралии. Были установлены организации, ответственные за проведение ОТЗ (ОТЗ-агентства). Затем в доступных источниках (веб-сайты ОТЗ-агентств; библиографической базе данных Medline, поисковых системах Yandex и Google с использованием ключевых слов «организация работы ОТЗ агентств», «финансирование деятельности ОТЗ агентств», «pharmaceutical», «reimbursement», «healthcare decision making», «funding») был проведен поиск релевантной информации об организации их деятельности и финансирования.

Результаты

Результаты. Установлено, что ОТЗ-агентство может быть как самостоятельной государственной или некоммерческой организацией, так и структурным подразделением государственного органа исполнительной власти. Основным источником финансирования ОТЗ-агентств являются бюджетные средства государства. Общий объем финансирования варьируется от 550 000 евро (Ирландия) до 63,1 млн фунтов в Великобритании, Уэльсе и Северной Ирландии у Национального Института здоровья и клинического совершенствования (англ. - National Institute for Clinical Excellence, NICE). Число сотрудников, занимающихся ОТЗ, в штате агентств различается: от 6,8 ставок в Управлении по вопросам медицинской информации и качества медицинских услуг (англ. - Health Information and Quality Authority, HIQA) в Ирландии до 604 ставок в штате NICE).

ОТЗ-агентствомеждународный опытоценка технологий здравоохраненияОТЗфинансированиеорганизация работыHTA-agencyinternational practicehealth technology assessmentHTAfundingorganizational structureReferencesDahabreh J., Chan J. A, Earley A. et al. Modeling and Simulation in the Context of Health Technology Assessment: Review of Existing Guidance, Future Research Needs, and Validity Assessment, 2017.Dahabreh J., Chan J. A, Earley A. et al. Modeling and Simulation in the Context of Health Technology Assessment: Review of Existing Guidance, Future Research Needs, and Validity Assessment, 2017.Ciani O., Jommi C. The role of health technology assessment bodies in shaping drug development. Drug Des. Devel. Ther. 2014; 8: 2273-2281.Ciani O., Jommi C. The role of health technology assessment bodies in shaping drug development. Drug Des. Devel. Ther. 2014; 8: 2273-2281.Akehurst R. L., Abadie E., Renaudin N., Sarkozy F. Variation in Health Technology Assessment and Reimbursement Processes in Europe. Value Heal. 2017; 20 (1): 67-76.Akehurst R. L., Abadie E., Renaudin N., Sarkozy F. Variation in Health Technology Assessment and Reimbursement Processes in Europe. Value Heal. 2017; 20 (1): 67-76.Jackson T. J. Health technology assessment in Australia: challenges ahead. Med. J. Aust. 2007; 187 (5): 262-4.Jackson T. J. Health technology assessment in Australia: challenges ahead. Med. J. Aust. 2007; 187 (5): 262-4.Lopert R., Viney R. Revolution then evolution: The advance of health economic evaluation in Australia. Z. Evid. Fortbild. Qual. Ge-sundhwes. 2014; 108 (7): 360-6.Lopert R., Viney R. Revolution then evolution: The advance of health economic evaluation in Australia. Z. Evid. Fortbild. Qual. Ge-sundhwes. 2014; 108 (7): 360-6.Allen N., Walker S. R., Liberti L., Salek S. Health Technology Assessment (HTA) Case Studies : Factors Influencing Divergent HTA Reimbursement Recommendations. Value Heal. 2017; 20 (3): 320-8.Allen N., Walker S. R., Liberti L., Salek S. Health Technology Assessment (HTA) Case Studies : Factors Influencing Divergent HTA Reimbursement Recommendations. Value Heal. 2017; 20 (3): 320-8.Chamova J., Stellalliance A. B. Mapping of HTA national organisations, programmes and processes in EU and Norway, 2017. [Electronic resource] URL: https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/2018_mapping_npc_en.pdf. Accessed: 10.04.2019.Chamova J., Stellalliance A. B. Mapping of HTA national organisations, programmes and processes in EU and Norway, 2017. [Electronic resource] URL: https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/2018_mapping_npc_en.pdf. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Austria, 2009. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/Austria.asp. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Austria, 2009. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/Austria.asp. Accessed: 10.04.2019.Austria - Pharmaceutical country profile, 2010. URL: http://apps.who.int/medicinedocs/documents/s19731en/s19731en.pdf. Accessed: 10.04.2019.Austria - Pharmaceutical country profile, 2010. URL: http://apps.who.int/medicinedocs/documents/s19731en/s19731en.pdf. Accessed: 10.04.2019.Leopold C., Habl C., Vogler S., Morak S. PPRI Pharma Profile Austria. Vienna: Pharmaceutical Pricing and Reimbursement Information (PPRI), 2008.Leopold C., Habl C., Vogler S., Morak S. PPRI Pharma Profile Austria. Vienna: Pharmaceutical Pricing and Reimbursement Information (PPRI), 2008.Franken M., Polain M. le, Cleemput I., Koopmanschap M. Policies Similarities and differences between five European drug reimbursement systems. Int. J. Heal. Technol. Assess. 2012; 28 (4): 34957.Franken M., Polain M. le, Cleemput I., Koopmanschap M. Policies Similarities and differences between five European drug reimbursement systems. Int. J. Heal. Technol. Assess. 2012; 28 (4): 34957.EUnetHTA. An analysis of HTA and reimbursement procedures in EUnetHTA partner countries : final report, 2017. [Electronic resource] URL: https://www.eunethta.eu/an-analysis-of-hta-and-reim-bursement-procedures-in-eunethta-partner-countries-final-report/. Accessed: 10.04.2019.EUnetHTA. An analysis of HTA and reimbursement procedures in EUnetHTA partner countries : final report, 2017. [Electronic resource] URL: https://www.eunethta.eu/an-analysis-of-hta-and-reim-bursement-procedures-in-eunethta-partner-countries-final-report/. Accessed: 10.04.2019.Franken M., Stolk E., Scharringhausen T., et al. A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. Health Policy. 2015; 119 (2): 195202.Franken M., Stolk E., Scharringhausen T., et al. A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. Health Policy. 2015; 119 (2): 195202.Allen N., Liberti L., Walker S. R., Salek S. A Comparison of Reimbursement Recommendations by European HTA Agencies : Is There Opportunity for Further Alignment ? Front. Pharmacol. 2017; 8: 384.Allen N., Liberti L., Walker S. R., Salek S. A Comparison of Reimbursement Recommendations by European HTA Agencies : Is There Opportunity for Further Alignment ? Front. Pharmacol. 2017; 8: 384.Barnieh L., Manns B., Harris A. et al. Health Policy Analysis A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Cooperation and Development Countries. Value Heal. 2014; 17 (1): 98-108.Barnieh L., Manns B., Harris A. et al. Health Policy Analysis A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Cooperation and Development Countries. Value Heal. 2014; 17 (1): 98-108.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Germany, 2009. [Electronic resource] [URL: https://tools.ispor.org/htaroadmaps/Ger-many.asp. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Germany, 2009. [Electronic resource] [URL: https://tools.ispor.org/htaroadmaps/Ger-many.asp. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Ireland, 2009. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/Ireland.asp. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Ireland, 2009. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/Ireland.asp. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Canada, 2011. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/CanadaPh-arm.asp. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Canada, 2011. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/CanadaPh-arm.asp. Accessed: 10.04.2019.Лемешко В.А., Тепцова Т.С. Лекарственное обеспечение и оценка медицинских технологий в системе здравоохранения Канады. Медицинские технологии. Оценка и выбор. 2018; 1 (31): 30-39Lemeshko V. A., Teptsova T. S. Drug Supply and Health Technology Assessment in Canada’s Health Care System. Medical Technologies. Assessment and Choice. 2018; 1 (31): 30-39 (in Russ).Paris V., Docteur E. Pharmaceutical Pricing and Reimbursement Policies in Canada. OECD. 2006 (Health Working Papers No. 24).Paris V., Docteur E. Pharmaceutical Pricing and Reimbursement Policies in Canada. OECD. 2006 (Health Working Papers No. 24).Husereau D., Dempster W., Blanchard A., Chambers J. Evolution of Drug Reimbursement in Canada: The Pan-Canadian Pharmaceutical Alliance for New Drugs. Value Heal. 2014; 17 (8): 888-94.Husereau D., Dempster W., Blanchard A., Chambers J. Evolution of Drug Reimbursement in Canada: The Pan-Canadian Pharmaceutical Alliance for New Drugs. Value Heal. 2014; 17 (8): 888-94.Zuidberg C. The Pharmaceutical System of the Netherlands. A Comparative Analysis Between the Dutch Out-patient Pharmaceutical System, in Particular the Pricing and Reimbursement Characteristics, and Those of the Other European Union Member States, with a Special Focus on Tendering-like Systems, 2010. [Electronic resource] URL: http://apps.who.int/medicinedocs/documents/s23167en/s23167en.pdf. Accessed: 10.04.2019.Zuidberg C. The Pharmaceutical System of the Netherlands. A Comparative Analysis Between the Dutch Out-patient Pharmaceutical System, in Particular the Pricing and Reimbursement Characteristics, and Those of the Other European Union Member States, with a Special Focus on Tendering-like Systems, 2010. [Electronic resource] URL: http://apps.who.int/medicinedocs/documents/s23167en/s23167en.pdf. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - United Kingdom, 2008. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/ UK.asp. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - United Kingdom, 2008. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/ UK.asp. Accessed: 10.04.2019.Salas-vega S., Bertling A., Mossialos E. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy. 2016; 120 (10): 1104-14.Salasvega S., Bertling A., Mossialos E. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy. 2016; 120 (10): 1104-14.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Scotland, 2008. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/Scot-land.asp. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Scotland, 2008. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/Scot-land.asp. Accessed: 10.04.2019.Тепцова Т.С., Лемешко В.А. Оценка технологий здравоохранения в Шотландии. Медицинские технологии. Оценка и выбор. 2018; 2 (32): 34-41 DOI: 10.31556/2219-0678.2018.32.2.034-041.Teptsova N. S., Lemeshko V. A. Health Technology Assessment in Scotland. Medical Technologies. Assessment and Choice. 2018; S 2 (32): 34-41 (in Russ). DOI: 10.31556/2219-0678.2018.32.2.034-041.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - France, 2009. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/France.asp/. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - France, 2009. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/France.asp/. Accessed: 10.04.2019.HAS. Pricing & Reimbursement of drugs and HTA policies in France Medicinal Products in France, 2014. [Electronic resource] URL: https://www.has-sante.fr/portail/upload/docs/application/pdf/2014-03/pricing_reimbursement_of_drugs_and_hta_policies_in_france.pdf. Accessed: 10.04.2019.HAS. Pricing & Reimbursement of drugs and HTA policies in France Medicinal Products in France, 2014. [Electronic resource] URL: https://www.has-sante.fr/portail/upload/docs/application/pdf/2014-03/pricing_reimbursement_of_drugs_and_hta_policies_in_france.pdf. Accessed: 10.04.2019.Lopes S. D., Marty C., Berdai D. PHIS Pharma Profile: France. Vienna: Pharmaceutical Health Information System (PHIS), 2011.Lopes S. D., Marty C., Berdai D. PHIS Pharma Profile: France. Vienna: Pharmaceutical Health Information System (PHIS), 2011.Blachier C., Kanavo P. France pharmaceutical pricing and reimbursement. [Electronic resource] URL: http://plg-group.com/wp-con-tent/uploads/2014/03/France-Pharmaceutical-Pricing-and-Reim-bursement-Corinne-Bl.pdf. Accessed: 10.04.2019.Blachier C., Kanavo P. France pharmaceutical pricing and reimbursement. [Electronic resource] URL: http://plg-group.com/wp-con-tent/uploads/2014/03/France-Pharmaceutical-Pricing-and-Reim-bursement-Corinne-Bl.pdf. Accessed: 10.04.2019.Anell A., Pers U. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Eur. J. Heal. Econ. 2005; 6 (3): 274-9.Anell A., Pers U. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Eur. J. Heal. Econ. 2005; 6 (3): 274-9.Procedure guidance for listing medicines on the Pharmaceutical Benefits Scheme (including consideration of vaccines for the National Immunisation Program), Version 1.4, 2019. [Electronic resource] URL: http://www.pbs.gov.au/industry/listing/procedure-guidance/files/pro-cedure-guidance-listing-medicines-on-the-pbs.pdf. Accessed: 10.04.2019.Procedure guidance for listing medicines on the Pharmaceutical Benefits Scheme (including consideration of vaccines for the National Immunisation Program), Version 1.4, 2019. [Electronic resource] URL: http://www.pbs.gov.au/industry/listing/procedure-guidance/files/pro-cedure-guidance-listing-medicines-on-the-pbs.pdf. Accessed: 10.04.2019.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0), 2016. [Electronic resource] URL: https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf. Accessed: 10.04.2019.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0), 2016. [Electronic resource] URL: https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf. Accessed: 10.04.2019.van Wilder P.B., Bormans V.V., Dupont A.G. Relative efficacy and effectiveness assessment of new pharmaceuticals in three EU member states : current practices and outcome agreement between Belgium, the Netherlands and France. Eur. J. Clin. Pharmacol. 2013; 69 (12): 2037-43.van Wilder P.B., Bormans V.V., Dupont A.G. Relative efficacy and effectiveness assessment of new pharmaceuticals in three EU member states : current practices and outcome agreement between Belgium, the Netherlands and France. Eur. J. Clin. Pharmacol. 2013; 69 (12): 2037-43.Davidova J., Praznovcova L., Lundborg C.S. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden. Pharm. World Sci. 2008; 30 (1): 57-64.Davidova J., Praznovcova L., Lundborg C.S. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden. Pharm. World Sci. 2008; 30 (1): 57-64.Jansson S. Implementing accountability for reasonableness -the case of pharmaceutical reimbursement in Sweden. Health Econ. Policy Law. 2007; 2 (Pt 2): 153-71.Jansson S. Implementing accountability for reasonableness -the case of pharmaceutical reimbursement in Sweden. Health Econ. Policy Law. 2007; 2 (Pt 2): 153-71.Onten J., Ronnholm G., Skiold P. PPRI Pharma Profile Sweden. Vienna: Pharmaceutical Pricing and Reimbursement Information (PPRI), 2017.Onten J., Ronnholm G., Skiold P. PPRI Pharma Profile Sweden. Vienna: Pharmaceutical Pricing and Reimbursement Information (PPRI), 2017.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Sweden, 2009. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/Swe-den.asp. Accessed: 10.04.2019.ISPOR Global Health Technology Assessment Road Map. Pharmaceutical HTA and Reimbursement Processes - Sweden, 2009. [Electronic resource] URL: https://tools.ispor.org/htaroadmaps/Swe-den.asp. Accessed: 10.04.2019.Tilson L., Leary A. O., Usher C., Barry M. Pharmacoeconomic Evaluation in Ireland A Review of the Process. Pharmacoeconomics. 2010; 28 (4): 307-22.Tilson L., Leary A. O., Usher C., Barry M. Pharmacoeconomic Evaluation in Ireland A Review of the Process. Pharmacoeconomics. 2010; 28 (4): 307-22.Barry M., Tilson L. Recent developments in pricing and reimbursement of medicines in Ireland. Expert. Rev. Pharmacoecon. Outcomes Res. 2007; 7 (6): 605-11.Barry M., Tilson L. Recent developments in pricing and reimbursement of medicines in Ireland. Expert. Rev. Pharmacoecon. Outcomes Res. 2007; 7 (6): 605-11.Sandmann F. G., Franken M. G., Steenhoek A., Koopmanschap M. A. Do reassessments reduce the uncertainty of decision making ? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. Health Policy. 2013; 112 (3): 285-96.Sandmann F. G., Franken M. G., Steenhoek A., Koopmanschap M. A. Do reassessments reduce the uncertainty of decision making ? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. Health Policy. 2013; 112 (3): 285-96.Dupree R., Pasman P. Specialist drugs package management. Zorginstituut Nederland, 2013. [Electronic resource] URL: https://en-glish.zorginstituutnederland.nl/publications/reports/2013/12/03/spe-cialist-drugs-package-management. Accessed: 10.04.2019.Dupree R., Pasman P. Specialist drugs package management. Zorginstituut Nederland, 2013. [Electronic resource] URL: https://en-glish.zorginstituutnederland.nl/publications/reports/2013/12/03/spe-cialist-drugs-package-management. Accessed: 10.04.2019.Franken M., Nilsson F., Koopmanschap M. Unravelling Drug Reimbursement Outcomes : A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. Pharmacoeconomics. 2013; 31 (9): 781-97.Franken M., Nilsson F., Koopmanschap M. Unravelling Drug Reimbursement Outcomes : A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. Pharmacoeconomics. 2013; 31 (9): 781-97.Cleemput I. European drug reimbursement systems legitimacy : Five-country comparison and policy tool. Int. J. Technol. Assess. Health Care. 2012; 28 (4): 358-66.Cleemput I. European drug reimbursement systems legitimacy : Five-country comparison and policy tool. Int. J. Technol. Assess. Health Care. 2012; 28 (4): 358-66.OECD. Pharmaceutical reimbursement and pricing in Germany, 2018. [Electronic resource] URL: http://www.oecd.org/els/health-sys-tems/Pharmaceutical-Reimbursement-and-Pricing-in-Germany.pdf. Accessed: 10.04.2019.OECD. Pharmaceutical reimbursement and pricing in Germany, 2018. [Electronic resource] URL: http://www.oecd.org/els/health-sys-tems/Pharmaceutical-Reimbursement-and-Pricing-in-Germany.pdf. Accessed: 10.04.2019.Leverkus F., Chuang-stein C. Implementation of AMNOG: An industry perspective. Biometrical J. 2016; 58 (1): 76-88.Leverkus F., Chuang-stein C. Implementation of AMNOG: An industry perspective. Biometrical J. 2016; 58 (1): 76-88.Staab T. R., Walter M., Nesurini S. M. et al. Market withdrawals of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. Health Econ. Rev. 2018; 8 (1): 23.Staab T. R., Walter M., Nesurini S. M. et al. Market withdrawals of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. Health Econ. Rev. 2018; 8 (1): 23.Chamova J, Ab S. Mapping of HTA national organisations, programmes and processes in EU and Norway Annexes. 2017. [Electronic resource] URL: https://ec.europa.eu/health/sites/health/files/technolo-gy_assessment/docs/2018_mapping_processes_annexes_en.pdf. Accessed: 10.04.2019.Chamova J, Ab S. Mapping of HTA national organisations, programmes and processes in EU and Norway Annexes. 2017. [Electronic resource] URL: https://ec.europa.eu/health/sites/health/files/technolo-gy_assessment/docs/2018_mapping_processes_annexes_en.pdf. Accessed: 10.04.2019.Sozialgesetzbuch (SGB) Funftes Buch (V) - Gesetzliche Kran-kenversicherung - (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477) § 139c Finanzierung. [Electronic resource] URL: https://www.gesetze-im-internet.de/sgb_5/BJNR024820988.html. Accessed: 10.04.2019.Sozialgesetzbuch (SGB) Funftes Buch (V) - Gesetzliche Kran-kenversicherung - (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477) § 139c Finanzierung. [Electronic resource] URL: https://www.gesetze-im-internet.de/sgb_5/BJNR024820988.html. Accessed: 10.04.2019.Vogel L. Health Canada wants more funds from pharma. CMAJ. 2017; 189 (24): E845-E846.Vogel L. Health Canada wants more funds from pharma. CMAJ. 2017; 189 (24): E845-E846.CADTH. Industry Application Fees: An Administrative Review, September 26, 2016, 2016. [Electronic resource] URL: https://www.cadth.ca/sites/default/files/pdf/ApplicationFeeAdministrativeReview_Final.pdf. Accessed: 10.04.2019.CADTH. Industry Application Fees: An Administrative Review, September 26, 2016, 2016. [Electronic resource] URL: https://www.cadth.ca/sites/default/files/pdf/ApplicationFeeAdministrativeReview_Final.pdf. Accessed: 10.04.2019.

The authors declare that there are no conflicts of interest present.